Disitamab Vedotin (RC-48, RC 480-ADC) is an antibody-drug conjugate (ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer. It has average molecular weight of 149KDa. The DAR is n = ~3.8. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Type | Antibody-drug conjugate |
---|
ADC antibody | Disitamab |
---|
ADC cytotoxin (drug) | MMAE |
---|
Immunogen | EGFR2, HER2 |
---|
DAR (Drug to Antibody Ratio) | ~3.8 |
---|
Purity | 99% |
---|
Molecular Weight | 149kDa |
---|
Protein Concentration | 10mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | PBS buffer pH7.4 |